适应症-话题@MedSci

#适应症#

219篇内容 | 3030人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1336802, encodeId=6b5d133680226, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, objectType=article, longId=187183, objectId=a1b618e18333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b618e18333, replyNumber=0, likeNumber=67, createdTime=2020-02-03, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b618e18333, moduleTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b618e18333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336801, encodeId=d7181336801ee, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险, objectType=article, longId=186986, objectId=f35818698644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f35818698644, replyNumber=0, likeNumber=65, createdTime=2020-01-31, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f35818698644, moduleTitle=加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f35818698644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336800, encodeId=ddf8133680064, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生向欧盟申请将Spravato的适应症，扩展用于具有自杀倾向的抑郁症患者, objectType=article, longId=186453, objectId=c04718645351, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c04718645351, replyNumber=0, likeNumber=64, createdTime=2020-01-19, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c04718645351, moduleTitle=强生向欧盟申请将Spravato的适应症，扩展用于具有自杀倾向的抑郁症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c04718645351)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336799, encodeId=53271336e998d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=原研全人源阿达木单抗获批新适应症，为克罗恩病患者带来新的曙光!, objectType=article, longId=186386, objectId=7b2a186386f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b2a186386f6, replyNumber=0, likeNumber=67, createdTime=2020-01-18, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b2a186386f6, moduleTitle=原研全人源阿达木单抗获批新适应症，为克罗恩病患者带来新的曙光!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b2a186386f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336798, encodeId=4b611336e9894, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症, objectType=article, longId=185991, objectId=6b1e18599136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b1e18599136, replyNumber=0, likeNumber=71, createdTime=2020-01-11, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b1e18599136, moduleTitle=美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b1e18599136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336797, encodeId=e7201336e97c3, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局, objectType=article, longId=184654, objectId=946f18465458, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=946f18465458, replyNumber=0, likeNumber=80, createdTime=2019-12-14, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=946f18465458, moduleTitle=罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=946f18465458)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336796, encodeId=c5ae1336e969a, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, objectType=article, longId=184092, objectId=92cd1840921e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92cd1840921e, replyNumber=0, likeNumber=76, createdTime=2019-12-05, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92cd1840921e, moduleTitle=默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92cd1840921e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336795, encodeId=37e41336e953f, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准, objectType=article, longId=184025, objectId=7f2c18402514, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f2c18402514, replyNumber=0, likeNumber=85, createdTime=2019-12-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f2c18402514, moduleTitle=默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f2c18402514)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336794, encodeId=7c251336e9440, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=罗氏骁悉®狼疮性肾炎新适应症在华上市，同步启动卵巢关爱项目, objectType=article, longId=183846, objectId=778f1838464b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=778f1838464b, replyNumber=0, likeNumber=66, createdTime=2019-12-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=778f1838464b, moduleTitle=罗氏骁悉®狼疮性肾炎新适应症在华上市，同步启动卵巢关爱项目, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=778f1838464b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336793, encodeId=2db11336e933e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=雷珠单抗在华4大适应症全部进入医保！, objectType=article, longId=183757, objectId=6684183e57bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6684183e57bb, replyNumber=0, likeNumber=55, createdTime=2019-11-30, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6684183e57bb, moduleTitle=雷珠单抗在华4大适应症全部进入医保！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6684183e57bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336792, encodeId=f37d1336e921b, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=国内外周T细胞淋巴瘤原创药获批第二个适应症，这次是乳腺癌, objectType=article, longId=183430, objectId=68dd183430c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68dd183430c6, replyNumber=0, likeNumber=79, createdTime=2019-11-24, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68dd183430c6, moduleTitle=国内外周T细胞淋巴瘤原创药获批第二个适应症，这次是乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=68dd183430c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336791, encodeId=5b7e1336e9180, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=三代“格列卫”同台竞技尼洛替尼又一适应症获批, objectType=article, longId=183424, objectId=2fdc183424d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fdc183424d8, replyNumber=0, likeNumber=89, createdTime=2019-11-24, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fdc183424d8, moduleTitle=三代“格列卫”同台竞技尼洛替尼又一适应症获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fdc183424d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336790, encodeId=cb161336e90ab, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症, objectType=article, longId=183190, objectId=6e8f18319058, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e8f18319058, replyNumber=0, likeNumber=67, createdTime=2019-11-20, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e8f18319058, moduleTitle=欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e8f18319058)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336789, encodeId=b50d1336e89ff, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=葛兰素史克的狼疮药物Benlysta在欧洲获得适应症扩容, objectType=article, longId=182190, objectId=e74d182190ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e74d182190ad, replyNumber=0, likeNumber=62, createdTime=2019-11-01, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e74d182190ad, moduleTitle=葛兰素史克的狼疮药物Benlysta在欧洲获得适应症扩容, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e74d182190ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336788, encodeId=de471336e8828, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=“假药门”法律争议焦点科普之——超适应症用药违法吗？, objectType=article, longId=181518, objectId=f0cd1815184a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0cd1815184a, replyNumber=0, likeNumber=74, createdTime=2019-10-19, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0cd1815184a, moduleTitle=“假药门”法律争议焦点科普之——超适应症用药违法吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0cd1815184a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336787, encodeId=5e401336e877c, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=Nature：癌症患者或能从“超适应症”药物中获益, objectType=article, longId=180428, objectId=37fe1804288a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37fe1804288a, replyNumber=0, likeNumber=63, createdTime=2019-10-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37fe1804288a, moduleTitle=Nature：癌症患者或能从“超适应症”药物中获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37fe1804288a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336786, encodeId=d81a1336e86f2, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=20年首次突破！FDA批准卡格列净治疗“糖尿病肾病”适应症！, objectType=article, longId=180366, objectId=2ba31803668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2ba31803668c, replyNumber=0, likeNumber=87, createdTime=2019-10-02, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2ba31803668c, moduleTitle=20年首次突破！FDA批准卡格列净治疗“糖尿病肾病”适应症！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2ba31803668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336785, encodeId=14161336e856e, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=V-A ECMO在心源性休克中的应用：适应症、操作方式及现有证据, objectType=article, longId=177974, objectId=4f791e7974e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f791e7974e5, replyNumber=0, likeNumber=68, createdTime=2019-08-21, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f791e7974e5, moduleTitle=V-A ECMO在心源性休克中的应用：适应症、操作方式及现有证据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f791e7974e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336784, encodeId=972d1336e84d9, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, objectType=article, longId=177713, objectId=d3701e7713cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3701e7713cf, replyNumber=0, likeNumber=57, createdTime=2019-08-17, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3701e7713cf, moduleTitle=强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3701e7713cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1336783, encodeId=1fbf1336e83cb, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, objectTitle=**肿瘤学数字疗法获FDA批准，可针对所有癌症适应症, objectType=article, longId=176740, objectId=0a581e674060, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a581e674060, replyNumber=0, likeNumber=70, createdTime=2019-08-04, rootId=0, userName=644982816_68283321, userId=3dd32500118, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a581e674060, moduleTitle=**肿瘤学数字疗法获FDA批准，可针对所有癌症适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a581e674060)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

适应症

2020-05-29

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣

2020-02-03

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

加拿大卫生部批准卡那列净的新适应症，以降低2型糖尿病患者肾病相关风险

2020-01-31

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

强生向欧盟申请将Spravato的适应症，扩展用于具有自杀倾向的抑郁症患者

2020-01-19

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

原研全人源阿达木单抗获批新适应症，为克罗恩病患者带来新的曙光!

2020-01-18

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

美国FDA批准补充性新药申请（sNDA），扩展MYCAMINE（注射用米卡芬净）的适应症，用于治疗小于4个月大的小儿侵袭性念珠菌血症

2020-01-11

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

罗氏乳腺癌创新靶向药帕捷特®又一适应症在中国获批，开启HER2阳性晚期乳腺癌治疗新格局

2019-12-14

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

默克PD-1单抗KEYTRUDA（pembrolizumab）目前在美国获批的所有适应症：14种癌症的治疗

2019-12-05

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

默克的PD-1单抗Keytruda获得国内非小细胞肺癌适应症的第三次批准

2019-12-04

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

罗氏骁悉®狼疮性肾炎新适应症在华上市，同步启动卵巢关爱项目

2019-12-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

雷珠单抗在华4大适应症全部进入医保！

2019-11-30

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

国内外周T细胞淋巴瘤原创药获批第二个适应症，这次是乳腺癌

2019-11-24

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

三代“格列卫”同台竞技尼洛替尼又一适应症获批

2019-11-24

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

欧洲药品管理局CHMP建议批准7种药物上市和2种药物扩展适应症

2019-11-20

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

葛兰素史克的狼疮药物Benlysta在欧洲获得适应症扩容

2019-11-01

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

“假药门”法律争议焦点科普之——超适应症用药违法吗？

2019-10-19

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

Nature：癌症患者或能从“超适应症”药物中获益

2019-10-04

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

20年首次突破！FDA批准卡格列净治疗“糖尿病肾病”适应症！

2019-10-02

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

V-A ECMO在心源性休克中的应用：适应症、操作方式及现有证据

2019-08-21

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

强生BTK抑制剂Imbruvica获欧盟批准扩大两个适应症：慢性淋巴细胞白血病和瓦尔德斯特罗姆巨球蛋白血症

2019-08-17

644982816_68283321 (审核中...)

前往app查看评论内容

#适应症#

**肿瘤学数字疗法获FDA批准，可针对所有癌症适应症

2019-08-04

科室
- - 订阅+
  - 更多科室
工具
服务